DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases.
1996 Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA
2000 Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Prognostic factors in human colorectal cancer.
1997 A. R., Bianco; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; G., Tortora; F., Ciardiello
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.
2003 DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
2007 Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
Survival Analysis by means of a novel Neural Network Model
2003 Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
2007 DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
[Exemestane in the treatment of breast carcinoma: recent findings]
2008 DE LAURENTIIS, Michelino; Carmen, Criscitiello; Agnese, Montanino; Claudette, Falato; Monica, Plaitano
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
2011 Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
2011 Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; Mcgale, P; Pan, Hc; Taylor, C; Wang, Yc; Dowsett, M; Ingle, J; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
2010 Gori, S; Di Maio, M; Pinto, C; Alabiso, O; Baldini, E; Beretta, Gd; Caffo, O; Caroti, C; Crinò, L; DE LAURENTIIS, Michelino; Dinota, A; Di Vito, F; Gebbia, V; Giustini, L; Graiff, C; Guida, M; Lelli, G; Lombardo, M; Muggiano, A; Puglisi, F; Romito, S; Salvagno, L; Tagliaferri, P; Terzoli, E; Venturini, M; AIOM Working Group Interaction with Regional, Sections
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
2003 Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. | 1.1 Articolo in rivista | 1996 | Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino | |
| NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA | 1.1 Articolo in rivista | 2000 | Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Prognostic factors in human colorectal cancer. | 1.1 Articolo in rivista | 1997 | A. R., Bianco; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; G., Tortora; F., Ciardiello | |
| Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. | 1.1 Articolo in rivista | 2003 | DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino | |
| IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino | |
| SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
| Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. | 1.1 Articolo in rivista | 2007 | Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino | |
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco | |
| Survival Analysis by means of a novel Neural Network Model | 1.1 Articolo in rivista | 2003 | Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
| EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. | 1.1 Articolo in rivista | 2007 | DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| [Exemestane in the treatment of breast carcinoma: recent findings] | 1.1 Articolo in rivista | 2008 | DE LAURENTIIS, Michelino; Carmen, Criscitiello; Agnese, Montanino; Claudette, Falato; Monica, Plaitano | |
| Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. | 1.1 Articolo in rivista | 2011 | Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm | |
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. | 1.1 Articolo in rivista | 2011 | Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; Mcgale, P; Pan, Hc; Taylor, C; Wang, Yc; Dowsett, M; Ingle, J; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). | 1.1 Articolo in rivista | 2010 | Gori, S; Di Maio, M; Pinto, C; Alabiso, O; Baldini, E; Beretta, Gd; Caffo, O; Caroti, C; Crinò, L; DE LAURENTIIS, Michelino; Dinota, A; Di Vito, F; Gebbia, V; Giustini, L; Graiff, C; Guida, M; Lelli, G; Lombardo, M; Muggiano, A; Puglisi, F; Romito, S; Salvagno, L; Tagliaferri, P; Terzoli, E; Venturini, M; AIOM Working Group Interaction with Regional, Sections | |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. | 1.1 Articolo in rivista | 2003 | Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara |